West Pharmaceutical Services, Inc.
Rank #240Capital ReturnWST · NYSE · Healthcare
West Pharmaceutical Services, Inc. (WST) — Rank #240 by gross profitability (GP/assets 0.27) · ROE 16.5% · Piotroski F-Score 7 / 9.
As-of 2026-09-28 · CIK 0000105770 · all metrics point-in-time as of the filing date.
About
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Show moreShow less
It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc.
was founded in 1923 and is headquartered in Exton, Pennsylvania.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- PA
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- westpharma.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-17 | 2024-12-31filed 2025-02-18 | 2023-12-31filed 2024-02-20 | 2022-12-31filed 2023-02-21 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 171.4 | 155.4 | 137.3 | 120.6 |
| Stock-based compensation | 23.8 | 18.7 | 23.3 | 23.7 |
| Change in receivables | (6.9) | 58.8 | (4.0) | 35.6 |
| Change in inventory | 62.8 | (42.0) | 13.5 | 49.8 |
| Change in payables | 17.9 | 2.9 | 4.4 | (2.8) |
| Operating cash flow | 754.8 | 653.4 | 776.5 | 724.0 |
| Investing | ||||
| Capital expenditures | 285.9 | 377.0 | 362.0 | 284.6 |
| Investing cash flow | (285.9) | (378.7) | (368.7) | (288.2) |
| Financing | ||||
| Debt issued | 0.0 | 164.7 | — | — |
| Debt repaid | 0.0 | 169.0 | — | 1.2 |
| Share repurchases | 134.0 | 560.9 | 438.3 | 202.8 |
| Dividends paid | 61.2 | 59.1 | 57.0 | 54.1 |
| Financing cash flow | (185.1) | (622.6) | (459.6) | (293.6) |
| Summary | ||||
| Free cash flow | 468.9 | 276.4 | 414.5 | 439.4 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?